RedHill Biopharma (RDHL) Non Operating Income (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Non Operating Income data on file, last reported at $47.5 million in Q2 2023.

• On a quarterly basis, Non Operating Income rose 1760.93% year-over-year to $47.5 million in Q2 2023; TTM through Jun 2023 was -$8.9 million, a 53.17% increase from a year earlier, with the FY2025 full-year figure at -$138000.0, down 102.02% from the prior year.
• Non Operating Income for Q2 2023 stood at $47.5 million, up from -$21.2 million in the prior quarter.
• Over the last five years, Non Operating Income for RDHL reached as high as $47.5 million in Q2 2023 and fell as low as -$63.9 million in Q4 2022.
• Historically, Non Operating Income has averaged -$417333.3 across 5 years, with a median of $3.0 million in 2020.
• Across the five-year window, Non Operating Income jumped 46522.22% in 2020 and tumbled 739.07% in 2021, its largest moves.
• Year by year, Non Operating Income stood at -$73000.0 in 2019, then surged by 6432.88% to $4.6 million in 2020, then tumbled by 739.07% to -$29.5 million in 2021, then tumbled by 116.18% to -$63.9 million in 2022, then soared by 174.36% to $47.5 million in 2023.
• Per Business Quant data, the three most recent Non Operating Income figures were $47.5 million in Q2 2023, -$21.2 million in Q1 2023, and -$63.9 million in Q4 2022.